Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radix Rehmanniae Preparata, commonly known as Shu Di Huang, is the processed (usually steamed and dried) tuber of Rehmannia glutinosa (Gaertn.) Libosch. ex Fisch. & C.A. Mey. It is a cornerstone of Traditional Chinese Medicine (TCM), valued for its "yin-enriching" and "blood-tonifying" properties. Pharmacologically, it contains a variety of bioactive compounds, including polysaccharides (RRPP), iridoid glycosides like catalpol, 5-hydroxymethylfurfural (5-HMF), and various sugars like mannotriose. Research indicates it possesses significant anti-inflammatory, anti-osteoporotic, and neuroprotective activities. It is used to treat osteoarthritis by modulating chondrocyte glucose metabolism, osteoporosis by improving bone mineral density and bone metabolism markers, and asthma by inhibiting airway remodeling and eosinophil infiltration. It is also frequently incorporated into multi-herb formulas for conditions such as Parkinson's disease, multiple sclerosis, and chemotherapy-induced myelosuppression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radix rehmanniae preparata.